Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jan 26.

Published in final edited form as: ACS Nano. 2020 Dec 22;15(1):1608–1626. doi: 10.1021/acsnano.0c09206

Figure 8. — Post-treatment effect of epitope-encapsulating nanoparticles on OVA-induced serological responses and allergic airway inflammation. Figure S5A outlines the experimental protocol. (A) Serum anti-OVA IgE level antibody titer was determined by ELISA. (B) Representative lung histology, as determined by H&E staining, scale bars represent 200 μm. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).

Figure 8. — Post-treatment effect of epitope-encapsulating nanoparticles on OVA-induced serological responses and allergic airway inflammation. Figure S5A outlines the experimental protocol. (A) Serum anti-OVA IgE level antibody titer was determined by ELISA. (B) Representative lung histology, as determined by H&E staining, scale bars represent 200 μm. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).